Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. - Wikidata - awgldk - TriplyDB

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

http://www.wikidata.org/entity/Q39652421

about

Voriconazole therapeutic drug monitoring.Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis Aspergillosis of bones and joints - a review from 2002 until today.Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.Direct injection HPLC micro method for the determination of voriconazole in plasma using an internal surface reversed-phase column.Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.Fast and reliable determination of voriconazole in human plasma by LC-APCI-MS/MS.In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3 Voriconazole pharmacokinetics in liver transplant recipients.Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD.CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.Inflammation is associated with voriconazole trough concentrations.Cyclodextrins.Steady-state plasma pharmacokinetics of oral voriconazole in obese adults.Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Voriconazole: a new triazole antifungal agent.Human pharmacogenomic variations and their implications for antifungal efficacy.Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.Recommendations for the treatment of fungal pneumonias.Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.Antifungal activity of amphotericin B and voriconazole against the biofilms and biofilm-dispersed cells of Candida albicans employing a newly developed in vitro pharmacokinetic model.Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.Influence of inflammation on voriconazole metabolism Systemic antifungal therapy: new options, new challenges.Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.Antifungal pharmacokinetics and pharmacodynamics Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature.In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.Pharmacokinetics of antifungal agents in children.

P2860

Q24542411-77DEA059-6856-4BCF-A3E4-3E0013A47D08 Q27009221-8669C39C-8042-4DA9-8C91-97C187020E74 Q28675835-7BFD378F-1092-455D-8D37-51C1453442CE Q30727401-E43782F3-5B61-41A7-973F-EF90B0FC330B Q30981299-D505B3D7-9A7D-480F-BBD0-1938EEDD39ED Q31115252-FACB4FB8-C0C4-4C4D-958E-2D00F8BFF386 Q33392206-118D9566-0367-460E-8FB8-6610F263719E Q33448151-3107D5EC-6E24-4E13-8350-D0D7B4037467 Q33574651-6887F33A-7CC3-42F9-955C-93A9AAD13FF9 Q33613685-6BF34D86-C27B-4482-83B9-18455033BDE0 Q33763177-02863501-10E6-4240-9F2B-A554BFBBEC64 Q33774641-309240FE-D666-4369-BF25-365CE3512915 Q33849298-5BC2A18A-828E-4303-BC71-E4CAC748C52F Q34020402-9877D4A4-922F-42EB-9560-38EF37640C69 Q34045383-3D56FEFA-6A50-48FF-AFA0-BD93A161833F Q34058346-3FC57EBF-295F-45BB-827F-5ACB36AACED0 Q34150923-D3C18BC8-1EB1-4B20-9637-CB54735B645C Q34290034-13C24D29-2323-410D-AC71-83660F32CBC3 Q34431984-FAE7D5AF-A2F0-4D26-94E0-5E49A7B10416 Q34596313-1F634615-086D-4ECF-B338-625510990D9F Q34597394-7A6B326E-61B1-45C8-8D68-548A4FCCDE8A Q34761190-1640E91E-5214-4A42-B4C8-CBE45235FC56 Q35004898-E0C2AEEA-5DC9-4414-A1C7-CF56EA56FA2D Q35026481-C9FCCB75-786F-41AF-80BF-B23DD657B2FB Q35069136-A61C5C7B-A99F-4316-AF63-316A5F4B19D5 Q35070838-EDBEF7B9-870B-4A6D-8686-A911C9148815 Q35105949-851C7429-94E8-403E-8A81-CE553B5F8F18 Q35183728-471E0ECB-770A-46A1-829E-2CC51FF8704D Q35270270-56D6B6D0-2140-403B-90BE-35E5BED64805 Q35318531-A530B1D9-263A-4246-BE45-31CE7CC2CE88 Q35364006-20DF5300-BD67-4748-89FF-172B5E60A619 Q35386048-D9289DF8-DFF5-4212-82FD-74622A2C5FFA Q35585219-9D1DBE9E-9BFB-4C62-96EF-222E1DB26D46 Q35598532-5F745AF1-D97E-4498-9FC3-806ED8DC2FAF Q35635830-71CE6444-C367-4549-B08E-ABB1E5071455 Q35663841-A85402AB-CB4C-4797-BF3F-679B0995FE60 Q35685548-3642A4B3-F7AE-4D0C-9E74-3993D3F22056 Q35959476-DB14BC89-B29D-427F-8F90-5348ED7A1198 Q36048229-2BFD40F0-EB1E-410D-A0B9-025695B46AA9 Q36163345-1FFEB208-779F-47B0-85E8-18A0F0229F7F

P2860

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

http://www.wikidata.org/entity/Q39652421

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Pharmacokinetics and safety of ...... oral-dose escalation regimens.

@en

Pharmacokinetics and safety of ...... oral-dose escalation regimens.

@nl

type

label

Pharmacokinetics and safety of ...... oral-dose escalation regimens.

@en

Pharmacokinetics and safety of ...... oral-dose escalation regimens.

@nl

prefLabel

Pharmacokinetics and safety of ...... oral-dose escalation regimens.

@en

Pharmacokinetics and safety of ...... oral-dose escalation regimens.

@nl

P1433

Q39652421-1A137EE5-778B-40E9-BAAC-D59DED6E8964

P1476

Q39652421-6E8A836E-A401-4275-A327-DDEFB0281716

P2093

Q39652421-1E2EF2BF-364E-4FAA-BB3C-CA4602B9316F

Q39652421-533217A2-C621-4D3D-8232-72E902193443

Q39652421-7A99E82D-81BB-473F-BFC5-001699C51B80

Q39652421-8A636253-A230-4EFD-B5B2-A541B67A8495

Q39652421-8BDFAF58-657E-4884-BEC5-5DE6CE6D772C

Q39652421-DC15CA56-863A-47FA-AF1F-08AAEAC508E0

P2860

Q39652421-01676C47-7771-4E20-8E6A-E3F7B2976C67

Q39652421-2169E83D-9096-43FB-B9F9-2904A4C722F6

Q39652421-2CA7BDC5-12D1-4D9F-8F3E-511A79BCAB8B

Q39652421-50D33445-16B8-4A69-BEE9-7FC668A025E7

Q39652421-64E2A994-070A-46C1-BE29-24F04A131450

Q39652421-70253625-DAEE-4643-94C3-1355339F992D

Q39652421-7BBB6681-5615-4BDD-8DBE-20D033D3C05F

Q39652421-98F90891-8D4A-4D4E-8345-9F2F7C1C3F34

Q39652421-9A56594C-C18C-47F6-B118-F1383FEF7907

Q39652421-9D83715E-C54D-47E6-8728-6F8EEBDB94F5

P304

Q39652421-0DC35664-AEEF-4B96-94FB-3A53C6A1F382

P31

Q39652421-032F19EA-0499-4864-8679-0ECDC280BBD5

P356

Q39652421-6F922D98-A813-4B0A-B666-1081454853E3

P407

Q39652421-6EA9C026-5419-4202-B1E3-C657CD927FC7

P433

Q39652421-200DABDB-EC77-4F7B-970E-F91CD6E2CB41

P478

Q39652421-B0AF6F5A-99AD-460B-A184-7717C09AEA5D

P577

Q39652421-C62798DF-FA62-4CDE-A6F4-3104B0826A88

P698

Q39652421-FF3317DE-B5FF-4366-9635-E4B05198D342

P932

Q39652421-33FE68A1-53BD-499C-92F5-7002F0C5F4BA

P356

AAC.46.8.2546-2553.2002

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics and safety of ...... oral-dose escalation regimens.

@en

P2093

Allen MJ

http://www.w3.org/2001/XMLSchema#string

Ghahramani P

http://www.w3.org/2001/XMLSchema#string

Greenhalgh K

http://www.w3.org/2001/XMLSchema#string

Kleinermans D

http://www.w3.org/2001/XMLSchema#string

Purkins L

http://www.w3.org/2001/XMLSchema#string

Wood N

http://www.w3.org/2001/XMLSchema#string

P2860

Biochemistry and molecular biology of the human CYP2C subfamily

Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species

In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species

A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei

In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.

In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates

In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection

Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.

In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.

In vitro evaluation of voriconazole against some clinically important fungi

P304

2546-2553

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.46.8.2546-2553.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12121931

http://www.w3.org/2001/XMLSchema#string

P932

127341

http://www.w3.org/2001/XMLSchema#string